Completed PHASE2 INTERVENTIONAL 2-arm NCT00142961

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment

Sponsor: National Institute on Drug Abuse (NIDA)

Conditions Attention Deficit Disorder With Hyperactivity Marijuana Abuse

Updated 8 times since 2017 Last updated: Apr 22, 2019 Started: Oct 31, 2005 Primary completion: Jan 31, 2007 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00142961, this PHASE2 trial focuses on Attention Deficit Disorder With Hyperactivity and Marijuana Abuse and remains completed. Sponsored by National Institute on Drug Abuse (NIDA), it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
May 2019 — Jan 2021 [monthly]

Completed PHASE2
Nov 2018 — May 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)
New York State Psychiatric Institute

Data source: New York State Psychiatric Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States